| Literature DB >> 35217936 |
Pauline Hilda Herroelen1, Robbe Heestermans1, Kristof Emmerechts1, Kristof Vandoorslaer1, Ingrid Wybo1, Denis Piérard1, Astrid Muyldermans2.
Abstract
With the increase in antimicrobial resistance, fast reporting of antimicrobial susceptibility testing (AST) results is becoming increasingly important. EUCAST developed a method for rapid AST (RAST) directly from the broth of positive blood cultures (BC). Inhibition zones are read after 4, 6, and 8 h, with specific breakpoints per time point. We evaluated the RAST method based on EUCAST disk diffusion methodology with inoculation of BC broth using WASPLab® (inclusive Colibrí™ and Radian®). Forty-nine non-duplicate strains were tested: Escherichia coli n = 17, Klebsiella pneumoniae n = 7, Pseudomonas aeruginosa n = 4, Acinetobacter baumannii n = 2, Staphylococcus aureus n = 10, Enterococcus faecalis n = 6, and Enterococcus faecium n = 3. Results were compared to direct AST and standardized AST. Good categorical agreement was obtained at all time points for all groups, except P. aeruginosa. RAST cut-offs for extended-spectrum β-lactamase (ESBL)-producing Enterobacterales enabled the detection of all included ESBL isolates (n = 5) at all time points, except for 1 E. coli ESBL after 4 h. RAST cut-offs for carbapenemase-producing Enterobacterales enabled the detection of only one carbapenemase after 6 h. However, all carbapenemases (n = 3) were correctly detected after 8 h. Two methicillin-resistant S. aureus were included; both were correctly categorized as cefoxitin-resistant at 6 and 8 h. At 4 h, there was insufficient growth for inhibition zone interpretation. EUCAST RAST is a fast supplementary tool for direct AST of positive BC. WASPLab® provides a significant advantage as pictures are made automatically implicating that we are not strictly bound to the time points for inhibition zone interpretation.Entities:
Keywords: Blood culture; Colibrí™; Direct AST; Radian® in-Line Carousel; Rapid AST; WASPLab®
Mesh:
Substances:
Year: 2022 PMID: 35217936 PMCID: PMC9042988 DOI: 10.1007/s10096-022-04421-8
Source DB: PubMed Journal: Eur J Clin Microbiol Infect Dis ISSN: 0934-9723 Impact factor: 5.103
Results of rapid AST and direct AST for Gram-negative bacteria, as compared to the standardized AST
| Rapid AST, 4 h | Rapid AST, 6 h | Rapid AST, 8 h | Direct AST | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UR, | ATU, | CA, n (%) | VME, | ME, | mE, | UR, | ATU, | CA, | VME, | ME, | mE, | UR, | ATU, | CA, | VME, | ME, | mE, | CA, | VME, | ME, | mE, | ||
TZP | 0 (0) | 12 (50.0) | 11 (91.7) | 0 (0) | 1 (16.7) | 0 (0) | 0 (0) | 13 (54.2) | 10 (90.9) | 0 (0) | 1 (20.0) | 0 (0) | 0 (0) | 15 (62.5) | 9 (100) | 0 (0) | 0 (0) | 0 (0) | 22 (91.7) | 2 (33.3) | 0 (0) | 0 (0) | |
CAZ | 0 (0) | 2 (8.3) | 19 (86.4) | 1 (20.0) | 0 (0) | 2 (9.1) | 0 (0) | 1 (4.2) | 21 (91.3) | 0 (0) | 0 (0) | 2 (8.7) | 0 (0) | 3 (12.5) | 19 (90.5) | 0 (0) | 0 (0) | 2 (9.5) | 21 (87.5) | 0 (0) | 0 (0) | 3 (12.5) | |
MEM | 0 (0) | 2 (8.3) | 11 (95.5) | – | 0 (0) | 1 (4.5) | 0 (0) | 0 (0) | 14 (95.8) | 0 (0) | 0 (0) | 1 (4.2) | 0 (0) | 0 (0) | 23 (95.8) | 0 (0) | 0 (0) | 1 (4.2) | 24 (100) | 0 (0) | 0 (0) | 0 (0) | |
CIP | 0 (0) | 5 (20.8) | 17 (89.5) | 0 (0) | 0 (0) | 2 (10.5) | 0 (0) | 3 (12.5) | 20 (95.2) | 0 (0) | 0 (0) | 1 (4.8) | 0 (0) | 3 (12.5) | 20 (95.2) | 0 (0) | 0 (0) | 1 (4.8) | 18 (75.0) | 2 (28.6) | 0 (0) | 4 (16.7) | |
AMK | 0 (0) | 9 (37.5) | 14 (93.3) | 1 (50.0) | 0 (0) | 0 (0) | 0 (0) | 6 (25.0) | 17 (94.4) | 1 (50.0) | 0 (0) | 0 (0) | 0 (0) | 5 (20.8) | 18 (94.7) | 1 (50.0) | 0 (0) | 0 (0) | 22 (91.7) | 1 (33.3) | 0 (0) | 1 (4.2) | |
SXT | 2 (8.3) | 0 (0) | 22 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 24 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 24 (100) | 0 (0) | 0 (0) | 0 (0) | 24 (100) | 0 (0) | 0 (0) | 0 (0) | |
TZP | – | – | – | – | – | – | 1 (25.0) | 1 (25.0) | 2 (100) | – | – | 0 (0) | 0 (0) | 3 (75.0) | 1 (100) | – | – | 0 (0) | 2 (50.0) | – | – | 2 (50.0) | |
CAZ | – | – | – | – | – | – | 1 (25.0) | 0 (0) | 2 (66.7) | – | – | 1 (33.3) | 0 (0) | 1 (25.0) | 2 (66.7) | – | – | 1 (33.3) | 2 (50.0) | – | – | 2 (50.0) | |
MEM | – | – | – | – | – | – | 1 (25.0) | 0 (0) | 3 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 3 (75.0) | 0 (0) | 0 (0) | 1 (25.0) | 4 (100) | 0 (0) | 0 (0) | 0 (0) | |
CIP | – | – | – | – | – | – | 1 (25.0) | 0 (0) | 3 (100) | 0 (0) | – | 0 (0) | 0 (0) | 0 (0) | 4 (100) | 0 (0) | – | 0 (0) | 3 (75.0) | 0 (0) | – | 1 (25.0) | |
AMK | – | – | – | – | – | – | 1 (25.0) | 0 (0) | 3 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 4 (100) | 0 (0) | 0 (0) | 0 (0) | 4 (100) | 0 (0) | 0 (0) | 0 (0) | |
FEP | – | – | – | – | – | – | 1 (33.3) | 0 (0) | 1 (50.0) | 0 (0) | 0 (0) | 1 (50.0) | 0 (0) | 0 (0) | 2 (66.7) | 0 (0) | 0 (0) | 1 (33.3) | 2 (66.7) | 0 (0) | 0 (0) | 1 (33.3) | |
MEM | 0 (0) | 0 (0) | 2 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (100) | 0 (0) | 0 (0) | 0 (0) | 2 (100) | 0 (0) | 0 (0) | 0 (0) | |
CIP | 0 (0) | 0 (0) | 2 (100) | 0 (0) | – | 0 (0) | 0 (0) | 0 (0) | 2 (100) | 0 (0) | – | 0 (0) | 0 (0) | 0 (0) | 2 (100) | 0 (0) | – | 0 (0) | 2 (100) | 0 (0) | – | 0 (0) | |
AMK | 0 (0) | 2 (100) | – | – | – | – | 0 (0) | 0 (0) | 2 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (100) | 0 (0) | 0 (0) | 0 (0) | 2 (100) | 0 (0) | 0 (0) | 0 (0) | |
SXT | 0 (0) | 1 (50.0) | 1 (100) | – | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (100) | 0 (0) | 0 (0) | 0 (0) | 2 (100) | 0 (0) | 0 (0) | 0 (0) | |
AMK, amikacin; AST, antimicrobial susceptibility testing; ATU, area of technical uncertainty; CA, categorical agreement; CAZ, ceftazidime; CIP, ciprofloxacin; FEP, cefepime; ME, major error; MEM, meropenem; mE, minor error; PTZ, piperacillin-tazobactam; SXT, trimethoprim-sulfamethoxazole; UR, unreadable zones; VME, very major error
Results of rapid AST and direct AST for Gram-positive bacteria, as compared to the standardized AST
FOX | 5 (50.0) | 1 (10.0) | 4 (100) | – | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 10 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 10 (100) | 0 (0) | 0 (0) | 0 (0) | 10 (100) | 0 (0) | 0 (0) | 0 (0) | |
CLI | 9 (90.0) | 0 (0) | 1 (100) | 0 (0) | – | 0 (0) | 1 (10.0) | 2 (20.0) | 7 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 3 (30.0) | 7 (100) | 0 (0) | 0 (0) | 0 (0) | 9 (90.0) | 0 (0) | 0 (0) | 1 (10.0) | |
AMP | 5 (55.6) | 0 (0) | 4 (100) | – | 0 (0) | 0 (0) | 1 (11.1) | 0 (0) | 8 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 9 (100) | 0 (0) | 0 (0) | 0 (0) | 9 (100) | 0 (0) | 0 (0) | 0 (0) | |
VAN | 3 (33.3) | 6 (66.7) | – | – | – | – | 1 (11.1) | 7 (77.8) | 1 (100) | 0 (0) | – | 0 (0) | 0 (0) | 8 (88.9) | 1 (100) | 0 (0) | – | 0 (0) | 8 (88.9) | 1 (50.0) | 0 (0) | 0 (0) | |
AST, antimicrobial susceptibility testing; AMP, ampicillin; ATU, area of technical uncertainty; CA, categorical agreement; CLI, clindamycin; FOX, cefoxitin; ME, major error; mE, minor error; UR, unreadable zones; VAN, vancomycin; VME, very major error